CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity
The treatment strategy of CAR-Ms combined with oAd-CD47 provides a promising, novel and effective treatment method for individualized targeted therapy of solid tumors.
Authors
- Anliang Huang
- Shichuan Hu (ORCID: https://orcid.org/0000-0003-3887-1779)
- Ping Cheng
- Zhongbing Qi (ORCID: https://orcid.org/0009-0003-4712-5097)
- Qingzhe Yang (ORCID: https://orcid.org/0009-0003-7054-6041)
- Jingyi Zhao (ORCID: https://orcid.org/0000-0002-2418-716X)
- Yao Zhang (ORCID: https://orcid.org/0000-0002-0776-1764)
- Qin Yu (ORCID: https://orcid.org/0000-0002-5703-8646)
- Xiaobo Xu (ORCID: https://orcid.org/0000-0002-4420-4369)
- Jianchuan Hu (ORCID: https://orcid.org/0009-0008-7823-9253)
- Chao Su (ORCID: https://orcid.org/0000-0002-1270-2064)
Institutions
- Sichuan University (CN)
- Chengdu Fifth People's Hospital (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1186/s40164-025-00696-7
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05